Clinical, morphological and microcirculatory criteria of local recurrence of the prostate cancer after HIFU therapy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim: to study the clinical, morphological and microcirculatory criteria for treatment efficiency and prognosis of local recurrence after HIFU. Materials and methods. On the basis of the urological department of Clinical Hospital «Russian Railways - Medicine» in Barnaul (the clinical base of the Department of Urology and Andrology with a course of Specialized Surgery of FGBOU VO «Altai State Medical University») for the period 2011-2018, a comprehensive examination and treatment of 240 patients with prostate cancer (PCa) by means of HIFU using «Ablatherm» was performed following transurethral resection of the prostate (TURP). The indication for HIFU was morphologically-proven PCa (stage T2a-cN0M0) in patients with contraindications due to comorbidities or those who refused from radical prostatectomy. Results. A decrease in PSA to 0.5 ng/ml or less was observed in 74% of patients. A stable PSA level for 3 years was observed in 76% of patients. PSA levels differed depending on the PCa risk group. In the low-risk PCa, negative biopsy was seen in 89.6% of cases, in comparison with 72.2% and 69.4% in intermediate and high-risk PCa, respectively. There was a significant decrease in the volume of the prostate in all patients with low-risk PCa. The largest decrease in prostate volume was observed 12 months after HIFU. Regarding recurrence-free survival after HIFU therapy, during followup of 3 years or more, 77% of patients didn’t have any signs of recurrence. A 3-year overall survival after HIFU was 83%. In addition, an increase in postoperative PSA levels, change in parameters of Doppler study and laser Doppler flowmetry at the area of the prostate during the period of 6-36 months after HIFU was associated with a significant increase in the risk of recurrence of PCa at biopsy. Conclusion. HIFU therapy is an effective treatment method for inducing prostate necrosis with minimal collateral damage to the surrounding tissue. The best results were achieved in patients with low-risk PCa. There were minimal adverse events after HIFU. In addition, in case of relapse after HIFU therapy, there is an opportunity for an early assessment of the efficiency and prognosis.

Full Text

Restricted Access

About the authors

A. I Neymark

FGBOU VO «Altai State Medical University» of the Ministry of Health of Russia

Email: urologagmu@mail.ru
MD, professor, Head of the Department of Urology and Andrology with a course of Specialized Surgery Barnaul, Russia

M. A Tachalov

Urology of Private Clinical Hospital «Russian Railways - Medicine»

Email: med7@mail.ru
Ph.D., oncourologist, Department Barnaul, Russia

B. A Neymark

FGBOU VO «Altai State Medical University» of the Ministry of Health of Russia

Email: urologagmu@mail.ru
MD, professor at the Department of Urology and Andrology with a course of Specialized Surgery Barnaul, Russia

V. P Levin

FGBOU VO «Altai State Medical University» of the Ministry of Health of Russia

assistant at the Department of Urology and Andrology with a course of Specialized Surgery Barnaul, Russia

References

  1. Bray F., Kiemeney L. Epidemiology of prostate cancer in Europe: patterns, trends and determinants. Management of prostate cancer: A multidisciplinary approach. Eds M. Bolla, H. van Poppel. Berlin: Springer-Verlag. 2017;1-11.
  2. Ferlay J., Colombet M., Soerjomataram I., et. al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953. doi: 10.1002/ijc.31937.
  3. Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Российской федерации. Экспериментальная и клиническая урология. 2011;2-3:6-7.
  4. Мерабишвили В.М., Петрова Н.Г., Атрощенко А.В., Харитонов М.В. Эпидемиология рака предстательной железы (популяционное исследование). Вопросы онкологии. 2014;4:457-463.
  5. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2015 году. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2016;236.
  6. Chaussy C.G., Thuroff S. High-Intensity focused ultrasound for the treatment of prostate cancer: a review. J. Endourol. 2017;31(1):30-37. Doi: 10.1089/ end.2016.0548.
  7. Warmuth M., Johansson T., Mad P. Systematic review of the efficacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer. Eur. Urol. 2010;58(6):803-815. Doi: 10.1016/j. eururo.2010.09.009.
  8. Неймарк А.И., Тачалов М.А., Неймарк Б.А. Адьювантная гормональная терапия у пациентов, перенесших HIFU-терапию по поводу локализованного рака предстательной железы. Онкоурология. 2014;3:69-72.
  9. Petraki C.D., Sfikas C.P. Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma. Histol. Histopathol. 2007;22:107-118. doi: 10.14670/HH-22.107.
  10. Chaussy C.G., Thuroff S. High-Intensity focused ultrasound for the treatment of prostate cancer: a review. J. Endourol. 2017;31(1):30-37. Doi: 10.1089/ end.2016.0548.
  11. Фомкин Р.Н., Воронина Е.С., Попков В.М., и др. Патоморфоз рака предстательной железы при лечении высокоинтенсивным сфокусированным ультразвуком (HIFU). Онкоурология. 2013; 1:55-62.
  12. Еникеев Д.В., Рапопорт Л.М., Крупинов Г.Е., и др. Фокальная терапия рака простаты: мечты или будущее? Вопросы урологии и андрологии. 2019;7(1):23-32.
  13. Hoogland A.M., Kweldam C.F., van Leenders G.J.L.H. Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review. Biomed. Res. Int. 2014;2014:341324. doi: 10.1155/2014/341324.
  14. Абоян И.А., Бадьян К.И., Пакус С.М., и др. Место HIFU в лечение рака предстательной железы: современное состояние проблемы (обзор литературы). Уральский медицинский журнал. 2017;2:69-74.
  15. Петровский Н.В., Глыбочко П.В., Долгушин М.Б., и др. Возможности позитронной эмиссионной томографии в диагностике рецидивов рака предстательной железы. Урология. 2019;5:126-131.
  16. Фомкин Р.Н., Шатылко Т.В. Надир ПСА как основной предиктор рецидива локализованного рака простаты после HIFU-аблации. Новости хирургии. 2016;24(5):489-496
  17. Аляев Ю.Г., Глыбочко П.В., Пушкарь Д.Ю. Урология. Российские клинические рекомендации. М.: Медфорум. 2018;544.
  18. Неймарк А.И., Тарасова Т.С. Патент № 2658460 от 24.10.2016. Способ диагностики рецидивов рака предстательной железы у мужчин).
  19. Васечкин В.И. Справочник по массажу. М.: Медицина. 1991;176).
  20. Козлов В.И., Гурова О.А., Литвин Ф.Б. и др. Расстройства тканевого кровотока, их патогенез и классификация. Регионарное кровообращение и микроциркуляция. 2007;1(21):75-76.
  21. Неймарк А.И., Кондратьева Ю.С., Неймарк Б.А. Лазерная допплеровская флоуметрия при заболеваниях мочеполовой системы. М.: Практическая медицина. 2011;104
  22. Неймарк А.И., Неймарк Б.А. Патент № 2361520 от 20.07.2020. Способ дифференциальной диагностики рака предстательной железы)
  23. Аляев Ю.Г., Крупинов Г.Е., Григорян В.А. Высокоинтенсивный фокусированный ультразвук в лечении рака предстательной железы. Онкоурология. 2017;2:42.
  24. Poissonnier L., Gelet A., Chapelon J.Y. et al. Results of transrectal focused ultra sound for the treatment of localized prostate cancer (120 patients with PSA
  25. Kweldam C.F., Kummerlin I.P., Nieboer D., et.al. Presence of invasive cribriform or intraductal growth at biopsy outperforms percentage grade 4 in predicting outcome of Gleason score 3+4=7 prostate cancer. Mod. Pathol. 2017;30:1126-1132.
  26. Rubin M.A., Buyyounouski M., Bagiella E., et.al. Microvessel density in prostate cancer: lack of association with tumor grade, pathologic stage and clinical outcome. Urology. 1999;53(3):542-547.
  27. Luczynska E., Gasinska A., Wilk W. Microvessel density and expression of vascular endothelial growth factor in clinically localized prostate cancer. Pol. J. Pathol. 2013;64(1):33-38.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies